Akari Therapeutics says AKTX-101 shows anti-tumor activity in preclinical urothelial cancer models

Akari Therapeutics says AKTX-101 shows anti-tumor activity in preclinical urothelial cancer models.

• Akari reported new preclinical urothelial cancer data for AKTX-101, a TROP2-targeted ADC using its PH1 RNA splicing modulator payload.
• AKTX-101 showed statistically significant tumor growth inhibition in the UM-UC-14 metastatic urothelial carcinoma model where Padcev had limited response.
• Switching Trodelvy-resistant tumors to AKTX-101 slowed growth, supporting activity in topoisomerase I payload-resistant disease.
• Results bolster a differentiated ADC sequencing strategy as prior exposure increases, targeting resistance seen with microtubule or topoisomerase I payloads.
• IND-enabling work continues, with a Phase 1 trial start targeted for mid-2027.